Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: Open-label, noncomparative, multicenter, long-term follow-up study

Epilepsia

Volumn 53, Issue 1, 2012, Pages 111-119

  Delanty, Norman ^a   Jones, John ^b   Tonner, Françoise ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b UCB PHARMA   (Belgium)

Author keywords

Absence seizures; Antiepileptic drugs; Clinical trial; Idiopathic generalized epilepsy; Myoclonic seizures; Tonic clonic seizures

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; VALPROIC ACID;

ADOLESCENT; ADULT; AGGRESSION; ANTICONVULSANT THERAPY; ANXIETY; ARTICLE; CHILD; CONVULSION; DEPRESSION; DISEASE FREE INTERVAL; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAND MAL SEIZURE; HEADACHE; HEART ARRHYTHMIA; HUMAN; IDIOPATHIC DISEASE; INFLUENZA; INSOMNIA; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYOCLONUS SEIZURE; NERVOUSNESS; OPEN STUDY; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOSIS; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SUICIDE; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTICONVULSANTS; ANXIETY; CHILD; CHILD, PRESCHOOL; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIRACETAM; SEIZURES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855427080     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2011.03300.x     Document Type: Article

References (46)

1. Abou-Khalil B, Schaich L,. (2005) Long-term efficacy of levetiracetam for partial seizures. Seizure 14: 577-585. (Pubitemid 41782480)
2. Alekar S, Leppik I, Montouris G, Harden C,. (2009) UCB Pharma antiepileptic drug pregnancy registry. Epilepsia 50: 245.
3. Allison PD,. (1995) Survival analysis using SAS: a practical guide. SAS Institute Inc., Cary, NC.
4. Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J,. (2005) Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 64: 1874-1878. (Pubitemid 40800700)
5. Bauer J, Ben-Menachem E, Kramer G, Fryze W, Da Silva S, Kasteleijn-Nolst Trenité DG,. (2006) Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand 114: 169-176. (Pubitemid 44185909)
6. Benbadis SR,. (2005) Practical management issues for idiopathic generalized epilepsies. Epilepsia 46 (Suppl. 9): 125-132. (Pubitemid 44921990)
7. Benbadis SR, Tatum WO, Gieron M,. (2003) Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology 61: 1793-1795. (Pubitemid 38020833)
8. Ben-Menachem E, Falter U,. (2000) Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41: 1276-1283.
9. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U,. (2007) Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy; Levetiracetam N01057 Study Group. Neurology 69: 1751-1760. (Pubitemid 350059304)
10. Biraben A, Allain H, Scarabin JM, Schuck S, Edan G,. (2000) Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 55: 1757-1758.
11. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ,. (2007) Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68: 402-408. (Pubitemid 46208740)
12. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I,. (2000) Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55: 236-242. (Pubitemid 30604624)
13. Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B,. (1998) Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 39: 81-88. (Pubitemid 28116846)
14. Crespel A, Genton P, Berramdane M, Coubes P, Monicard C, Baldy-Moulinier M, Gelisse P,. (2005) Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 65: 762-764. (Pubitemid 41285864)
15. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM,. (1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA 96: 15268-15273. (Pubitemid 30019801)
16. Dmitrienko A, Molenberghs G, Chuang-Stein C, Offen W,. (2005) Analysis of clinical trials using SAS®: a practical guide. SAS Institute Inc., Cary, NC.
17. Gelisse P, Genton P, Kuate C, Pesenti A, Baldy-Moulinier M, Crespel A,. (2004) Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 45: 1282-1286. (Pubitemid 39350341)
18. Genton P, Gelisse P, Thomas P, Dravet C,. (2000) Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 55: 1106-1109.
19. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, Lu Z,; N159 Study Group. (2006) Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66: 1654-1660. (Pubitemid 43964617)
20. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC,; Childhood Absence Epilepsy Study Group. (2010) Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 362: 790-799.
21. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C,; American Academy of Neurology; American Epilepsy Society. (2009) Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 50: 1237-1246.
22. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, Ryan LM,. (2001) The teratogenicity of anticonvulsant drugs. N Engl J Med 344: 1132-1138. (Pubitemid 32285234)
23. International League Against Epilepsy. (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30: 389-399.
24. Jallon P, Latour P,. (2005) Epidemiology of idiopathic generalized epilepsies. Epilepsia 46 (Suppl. 9): 10-14. (Pubitemid 44921975)
25. Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, Talaga P, Klitgaard H,. (2008) SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54: 715-720.
26. Kennedy F, Morrow J, Hunt S, Russel A, Smithson WH, Parsons L, Robertson I, Irwin B, Delanty N, Morrison PJ, Craig J,. (2010) Malformation risks of antiepileptic drugs (AEDs) in pregnancy: an update from the UK epilepsy and pregnancy register. Oral presentation presented at European Congress on Epileptology, Rhodes.
27. Knake S, Hamer HM, Schomburg U, Oertel WH, Rosenow F,. (1999) Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure 8: 314-317. (Pubitemid 29438112)
28. Levisohn PM, Mintz M, Hunter SJ, Yang H, Jones J,; N01103 Levetiracetam Study Group. (2009) Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, non-inferiority trial. Epilepsia 50: 2377-2389.
29. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B,. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101: 9861-9866. (Pubitemid 38869327)
30. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR,; SANAD Study group. (2007) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369: 1016-1026. (Pubitemid 46436125)
31. Mattson RH,. (2003) Overview: idiopathic generalized epilepsies. Epilepsia 44 (Suppl. 2): 2-6. (Pubitemid 36554624)
32. Mazurkiewicz-Beldzinska M, Szmuda M, Matheisel A,. (2010) Long-term efficacy of valproate versus lamotrigine in treatment of idiopathic generalized epilepsies in children and adolescents. Seizure 19: 195-197.
33. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW,; NEAD Study Group. (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360: 1597-1605.
34. Meador KJ, Baker GA, Browning N, Cohen MJ, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW,; NEAD Study Group. (2011) Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 134: 396-404.
35. Montouris GD, Biton V, Rosenfeld WE,. (2000) Nonfocal generalized tonic-clonic seizures: response during long-term topiramate treatment. Topiramate YTC/YTCE Study Group. Epilepsia 41 (Suppl. 1): S77-S81. (Pubitemid 30202347)
36. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW,. (2003) Psychiatric adverse events during levetiracetam therapy. Neurology 61: 704-706. (Pubitemid 37082613)
37. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J,; N166 Levetiracetam Study Group. (2008) Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70: 607-616. (Pubitemid 351294638)
38. Piña-Garza JE, Nordli D, Rating D, Yang H, Schiemann-Delgado J, Duncan B,; Levetiracetam N01009 Study Group. (2009a) Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia 50: 1141-1149.
39. Piña-Garza JE, Schiemann J, Yang H, Duncan B, Hadac J, Hunter S,. (2009b) Adjunctive levetiracetam in children aged 1 month to <4 years with partial-onset seizures: a long-term, multicenter, noncomparative, open-label, follow-up study. Epilepsia 50: 101, Abstract p470.
40. Rosenfeld W, Benbadis S, Edrich P, Tassinari CA, Hirsch E,. (2009) Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. Epilepsy Res 85: 72-80.
41. Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA,; the Liverpool Manchester Neurodevelopment Group and the UK Epilepsy and Pregnancy Register. (2011) Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 76: 383-389.
42. Shinnar S, Pellock JM, Conry JA,. (2009) Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol 13: 3-9.
43. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P,. (2000) Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures; European Levetiracetam Study Group. Epilepsia 41: 1179-1186.
44. Somerville ER,. (2008) Lack of seizure aggravation by levetiracetam in idiopathic generalized epilepsy: evidence from clinical trials. Epilepsia 49 (Suppl. 7): 456, Abstract 3.255.
45. Xu T, Bajjalieh SM,. (2001) SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 3: 691-698. (Pubitemid 32734246)
46. Yang H, Schiemann J, De La Loge C, Stalvey T, Jones J, LeGoff D, Mintz M,. (2009) Adjunctive levetiracetam in children and adolescents aged 4-16 years with partial-onset seizures: a long-term, multicenter, non-comparative, open-label follow-up study. Epilepsia 50 (Suppl. 10): 102, Abstract p471.